Abstract Introduction The JAVELIN Bladder 100 trial showed that maintenance avelumab
therapy after chemotherapy improved the survival of patients with advanced or metastatic …

Introduction First-line systemic therapy for metastatic urothelial carcinoma of the bladder
(mUC) consists of platinum-based chemotherapy in most patients and PD1/L1 inhibitors in …

Background: Nursing has been reported to effectively ameliorate physical movement,
significantly decrease postoperative complications, and markedly improve the quality of life …

膀胱癌是泌尿系统最为常见的恶性肿瘤, 严重影响了人们的健康和生活. 经尿道膀胱肿瘤电切术
是非肌层浸润性膀胱癌(NMIBC) 的主要治疗手段, 而术后易复发是治疗的一大难点 …

Abstract Objective The GOG 281/LOGS trial found that trametinib prolonged progression-
free survival (PFS) in patients with recurrent low-grade serous ovarian cancer (LGSOC) …

Simple Summary Researchers aim to assess the economic impact of testing predictive
biomarkers for immunotherapy in solid tumour treatment using immune checkpoint inhibitors …

Currently, checkpoint inhibitors, which function by triggering patients' own T cells to combat
tumor, are revolutionizing treatment for various types of cancer. Atezolizumab, a monoclonal …

Adding atezolizumab to platinum-based chemotherapy does not appear to be cost effective
as first-line treatment for metastatic urothelial cancer, according to researchers based in …